Interaksi Elvitegravir, kobisistat, emtrisitabin, dan tenofovir dan Emtrisitabin, rilpivirin, dan tenofovir

Elvitegravir, kobisistat, emtrisitabin, dan tenofovir dan Emtrisitabin, rilpivirin, dan tenofovir: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Emtrisitabin, rilpivirin, dan tenofovir (COMPLERA) · berlaku sejak 2025-07-16

Mayor

COMPLERA is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Mayor

Not Recommended with Other Antiretroviral Medications Because COMPLERA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Drugs Inducing or Inhibiting CYP3A Enzymes Rilpivirine is primarily metabolized by cytochrome P450 (CYP) 3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of RPV [see Contraindications (4) , Warnings and Precautions (5.7) , and Clinical Pharmacology (12.3) ] .

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Coadministration of RPV and drugs that inhibit CYP3A may result in increased plasma concentrations of RPV.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including TDF and FTC, components of COMPLERA, alone or in combination with other antiretrovirals.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Dari label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir (Genvoya) · berlaku sejak 2025-02-03

Mayor

GENVOYA should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Mayor

Not Recommended with Other Antiretroviral Medications GENVOYA is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration of GENVOYA with other antiretroviral medications for treatment of HIV-1 infection should be avoided.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Complete information regarding potential drug-drug interactions with other antiretroviral medications is not provided [see Contraindications (4) , Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including emtricitabine, a component of GENVOYA, and tenofovir DF, another prodrug of tenofovir, alone or in combination with other antiretrovirals.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.